Directed share issue in Targovax ASA (NO) — NOK 75 million

Carnegie acted as joint bookrunner in the directed share issue of 86,520,592 shares at a subscription price of NOK 7.25 per share. argovax is a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors. October 2020.